Novartis Reports One Year Results of Beovu (brolucizumabin) in P- III MERLIN Study to Treat Wet Age-Related Macular Degeneration

 Novartis Reports One Year Results of Beovu (brolucizumabin) in P- III MERLIN Study to Treat Wet Age-Related Macular Degeneration

Novartis Presents Results of Iptacopan in P-II Study for IgA Nephropathy at ERA-EDTA Congress

Shots:

  • The P- III MERLIN study involves assessing the efficacy & safety of Beovu (6 mg, q4w) vs aflibercept (2 mg, q4w) following the loading phase in patients with wet AMD who have persistent retinal fluid despite anti-VEGF therapy
  • Results: met its 1EPs i.e. non-inferiority in mean change in BCVA from baseline and superiority on 2EPs @ 1 yrs. Beovu (6mg, q4w) was associated with higher rates of IOI (9.3% vs 4.5%) which includes RV (0.8% vs 0.0%) & RO (2.0% vs 0.0%), overall rate of vision (4.8% vs 1.7%)
  • Novartis has decided on early termination of the RAPTOR & RAVEN studies, which assessed the efficacy & safety of Beovu in RVO, and included 6 initial monthly injections

Click here to­ read full press release/ article | Ref: Novartis | Image: BioSpace

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post